Plagril tablets 75mg, No. 30
Expiration Date: 11/2025
Russian Pharmacy name:
Плагрил таблетки 75мг, №30
prevention of thrombotic complications in patients with myocardial infarction, ischemic stroke or peripheral arterial occlusion;
prevention of thrombotic complications in acute coronary syndrome: with ST segment elevation if thrombolytic therapy is possible; without ST segment elevation (unstable angina pectoris, myocardial infarction without Q wave), incl. in patients undergoing stenting - in combination with acetylsalicylic acid.
Inside, regardless of the meal.
Prevention of ischemic disorders in patients after myocardial infarction, ischemic stroke or against the background of diagnosed peripheral arterial diseases: adults (including elderly patients) are prescribed 75 mg 1 time per day. Treatment should begin within 35 days after suffering a Q-shaped myocardial infarction and from 7 days to 6 months after ischemic stroke.
Acute coronary syndrome without ST segment elevation (unstable angina pectoris or myocardial infarction without Q wave formation): treatment should begin with a single loading dose of 300 mg, then continue to use the drug at a dose of 75 mg 1 time per day (while taking acetylsalicylic acid in a dose 75Ц325 mg / day). Since the use of acetylsalicylic acid in high doses is associated with a high risk of bleeding, the recommended dose should not exceed 100 mg. The course of treatment is up to 1 year.
Acute coronary syndrome with ST segment elevation (acute myocardial infarction): the drug is prescribed at a dose of 75 mg once a day, using an initial loading dose in combination with acetylsalicylic acid, in combination with or without thrombolytics. For patients over the age of 75, clopidogrel should be treated without a loading dose. Combination therapy is started as early as possible after the onset of symptoms and continued for at least 4 weeks.
| Film-coated tablets | 1 tab. |
| active substance: | |
| clopidogrel hydrogen sulfate | 97.875 mg |
| (equivalent to 75 mg clopidogrel) | |
| excipients: MCC (Avicel PH 112) - 211.125 mg; mannitol - 58 mg; croscarmellose sodium - 12 mg; colloidal silicon dioxide - 2 mg; magnesium stearate - 4 mg | |
| film shell: Opadry pink 03B54202 (hypromellose - 62.5%, titanium dioxide - 30.6%, macrogol 400 - 6.25%, iron dye red oxide - 0.65%) - 13.475 mg |
hypersensitivity to drug components;
severe liver failure;
hemorrhagic syndrome, acute bleeding (including intracranial hemorrhage) and diseases predisposing to its development (peptic ulcer of the stomach and duodenum in the acute stage, ulcerative colitis, tuberculosis, lung tumors, hyperfibrinolysis);
pregnancy;
lactation period (breastfeeding);
children under 18 years of age (safety and efficacy have not been established).
Precautions: moderate hepatic and / or renal impairment; injuries and conditions that increase the risk of bleeding (including surgery); simultaneous administration of acetylsalicylic acid, NSAIDs (including COX-2 inhibitors), heparin and inhibitors of glycoprotein IIb / IIIa receptors.